1. Home
  2. Advocacy
  3. Latest News and Practice Data
  4. FDA approves groundbreaking Alzheimer disease test

FDA approves groundbreaking Alzheimer disease test

A new test could be a game changer in diagnosing Alzheimer disease. The US FDA has approved the first in vitro diagnostic blood test to aid in identifying the condition.  

Why it matters: The test provides a more accessible method for detecting Alzheimer disease.

Who it's for: Adults aged 55 years and older who are showing signs or symptoms.

The Lumipulse G test detects amyloid plaques associated with Alzheimer disease using chemiluminescent enzyme immunoassay technology. This method offers high sensitivity and precision in biomarker quantification.

Go Deeper: Read the full FDA announcement.

Most Recent Content

  1. Connecticut genetic privacy law enacted after CAP, state advocacy
  2. CMS finalizes No Surprises Act dispute changes
  3. CAP members rally to shape federal policy
  4. CAP Review and Forecast: 2025 Financial Update
  5. CAP Review and Forecast: Informatics and Pathology Innovation 2025/2026
  6. View All